NasdaqGS:BIIBBiotechs
Assessing Biogen (BIIB) Valuation After Strong 1 Year Gains And Mixed Longer Term Returns
Biogen (BIIB) is back in focus after recent trading left the stock around $189.28, with returns over the past month and past 3 months contrasting with a weaker multi year picture.
See our latest analysis for Biogen.
Recent trading has left Biogen’s share price return slightly weaker over the past day but still positive over the past month and quarter. The 1 year total shareholder return of 56.52% contrasts with negative 3 and 5 year total shareholder returns.
If Biogen’s recent move has you...